Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P497

1Dept of Exp. Medicine, University of L’Aquila, L’Aquila, Italy; 2Neuromed Institute, IRCCS, Pozzili, Italy; 3Pathology, San Salvatore Hospital, L’Aquila, Italy; 4Dept of Neuroscience, University La Sapienza, Rome, Italy; 5Dept of Experimental Medicine and Pathology, University La Sapienza, Rome, Italy.


The beta-HLH transcription factors NeuroD1 and ASH1 are frequently expressed by pituitary adenomas, both being present in all corticotroph, most clinically non-secreting (CNS) and a subset of GH and/or PRL-secreting adenomas. We wished to investigate the expression of the related beta-HLH factors neurogenins (Ngn) 1, 2 and 3 in the pituitary (n=4) and in a series of pituitary adenomas (n=45). RT-PCR was performed at different amplification cycles (up to 45) in all cases. Ngn1 was undetectable in all samples. Ngn2 transcripts were detected in 56% of pituitary adenomas by RT-PCR (33/45) and up to 73% after Southern blotting (33/45). Low levels of Ngn2 transcripts were also detected in some normal pituitary samples. Preliminary data from immunohistochemistry are confirming Ngn2 protein expression and its nuclear localization in pituitary adenomas and a subset of normal pituitary cells. Ngn3 transcripts were undetectable in normal pituitaries and present in a subset of pituitary adenomas: 25% by RT-PCR (11/44), and 30% after Southern blotting (12/40). Overall, Ngn2/3 expression did not significantly correlate with tumour aggressiveness or with NeuroD1/ASH1 expression at a transcriptional level. Neither was their expression significantly influenced by tumor phenotype: Ngn2 was detected in all ACTH-secreting adenomas (100%) and in most CNS and PRL/GH/TSH-secreting adenomas too (67% and 74%, respectively), whereas Ngn3 was detected in a subset of all adenoma phenotypes (25% of ACTH-, 25% of CNS and 37% of GH/PRL/TSH-secreting adenomas, respectively). The expression of Ngn2 and to a lesser extent of Ngn3 in pituitary samples is consistent with their ontogenetic role in other neuroendocrine (NE) tissues, such as neural crest (Ngn2) and gastroenteropancreatic NE cells (Ngn3), and suggest a possible role in pituitary ontogenesis too. At the moment, there is no evidence for a significant role Ngn2/3 in pituitary tumorigenesis or in NeuroD1/ASH1 regulation.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.